Characterization of NS3 protease from an Egyptian HCV genotype 4a isolate

[1]  S. Kamal.  Hepatitis C genotype 4 therapy: increasing options and improving outcomes , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[2]  A. Nicosia,et al.  Hepatitis C vaccine: supply and demand. , 2008, The Lancet. Infectious diseases.

[3]  M. Manns,et al.  Cross-genotype-reactivity of the immunodominant HCV CD8 T-cell epitope NS3-1073. , 2008, Vaccine.

[4]  M. Kozal,et al.  Hepatitis C protease and polymerase inhibitors in development. , 2008, AIDS patient care and STDs.

[5]  R. Flisiak,et al.  Specifically targeted antiviral therapy for hepatitis C virus. , 2007, World journal of gastroenterology.

[6]  J. Pawlotsky,et al.  Hepatitis C virus: virology, diagnosis and management of antiviral therapy. , 2007, World journal of gastroenterology.

[7]  Todd M. Allen,et al.  Characterization of full‐length hepatitis C virus genotype 4 sequences , 2007, Journal of viral hepatitis.

[8]  B. Clotet,et al.  Complete nucleotide sequence of genotype 4 hepatitis C viruses isolated from patients co-infected with human immunodeficiency virus type 1. , 2007, Virus research.

[9]  M. Sällberg,et al.  A complete mutational fitness map of the hepatitis C virus nonstructural 3 protease: relation to recognition by cytotoxic T lymphocytes. , 2006 .

[10]  H. Sorgho,et al.  Enzyme-linked immunosorbent assay with worm vomit and cercarial secretions of Schistosoma mansoni to detect infections in an endemic focus of Burkina Faso , 2006, Journal of Helminthology.

[11]  M. Sallberg,et al.  In vivo clearance of hepatitis C virus nonstructural 3/4A-expressing hepatocytes by DNA vaccine-primed cytotoxic T lymphocytes. , 2005, The Journal of infectious diseases.

[12]  R. Bartenschlager,et al.  Relation between viral fitness and immune escape within the hepatitis C virus protease , 2005, Gut.

[13]  Brian L. Pearlman,et al.  Hepatitis C treatment update. , 2004, The American journal of medicine.

[14]  O. Weiland,et al.  Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3/4A gene , 2004, Gene Therapy.

[15]  J. Kalbfleisch,et al.  A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C , 2003, Hepatology.

[16]  Stanley M. Lemon,et al.  Regulation of Interferon Regulatory Factor-3 by the Hepatitis C Virus Serine Protease , 2003, Science.

[17]  P. Liljeström,et al.  Low dose and gene gun immunization with a hepatitis C virus nonstructural (NS) 3 DNA-based vaccine containing NS4A inhibit NS3/4A-expressing tumors in vivo , 2003, Gene Therapy.

[18]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[19]  T. Dharakul,et al.  Hepatitis C virus nonstructural 3 protein: recombinant NS3 protein of the Thai isolates as an antigen in a diagnostic assay. , 2002, Asian Pacific Journal of Allergy and Immunology.

[20]  F. Chisari,et al.  Determinants of Viral Clearance and Persistence during Acute Hepatitis C Virus Infection , 2001, The Journal of experimental medicine.

[21]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[22]  F. Chisari,et al.  Differential CD4+ and CD8+ T‐cell responsiveness in hepatitis C virus infection , 2001, Hepatology.

[23]  D L Thomas,et al.  Genetic epidemiology of hepatitis C virus throughout egypt. , 2000, The Journal of infectious diseases.

[24]  E. Schiff,et al.  Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology , 2000, Journal of gastroenterology and hepatology.

[25]  R. Bartenschlager,et al.  Replication of the hepatitis C virus. , 2000, Bailliere's best practice & research. Clinical gastroenterology.

[26]  R. Cortese,et al.  The solution structure of the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein provides new insights into its activation and catalytic mechanism. , 1999, Journal of molecular biology.

[27]  W. Secor,et al.  Neonatal Idiotypic Exposure Alters Subsequent Cytokine, Pathology, and Survival Patterns in Experimental Schistosoma mansoni Infections , 1999, The Journal of experimental medicine.

[28]  J. Encke,et al.  Genetic immunization generates cellular and humoral immune responses against the nonstructural proteins of the hepatitis C virus in a murine model. , 1998, Journal of immunology.

[29]  P. Simmonds,et al.  Antigenic variation of core, NS3, and NS5 proteins among genotypes of hepatitis C virus , 1997, Journal of clinical microbiology.

[30]  W. Stremmel,et al.  Establishment of persistent hepatitis C virus infection and replication in vitro. , 1997, The Journal of general virology.

[31]  P. Simmonds,et al.  Complete nucleotide sequence of a type 4 hepatitis C virus variant, the predominant genotype in the Middle East. , 1997, The Journal of general virology.

[32]  M. Chen,et al.  Immunogenicity and antigenicity of the ATPase/helicase domain of the hepatitis C virus non-structural 3 protein. , 1996, The Journal of general virology.

[33]  T. Santantonio,et al.  Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection , 1995, The Lancet.

[34]  S. Kunitada,et al.  Identification of the domain required for trans-cleavage activity of hepatitis C viral serine proteinase. , 1994 .

[35]  H. Claeys,et al.  Evaluation of Third‐Generation Screening and Confirmatory Assays for HCV Antibodies , 1994, Vox sanguinis.

[36]  R. Bartenschlager,et al.  Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions , 1993, Journal of virology.

[37]  G. Nemo,et al.  Hepatitis C virus infection in post-transfusion hepatitis. An analysis with first- and second-generation assays. , 1992, The New England journal of medicine.

[38]  G. Nemo,et al.  HEPATITIS C VIRUS INFECTION IN POST-TRANSFUSION HEPATITIS - AN ANALYSIS WITH FIRST - AND SECOND - GENERATION ASSAYS , 1991 .

[39]  M. Houghton,et al.  Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay , 1991, The Lancet.

[40]  R. Fletterick,et al.  Detection of a trypsin-like serine protease domain in flaviviruses and pestiviruses. , 1989, Virology.

[41]  H. Okayama,et al.  High-efficiency transformation of mammalian cells by plasmid DNA. , 1987, Molecular and cellular biology.

[42]  Paul R. Thompson.  AUTHOR! , 1982, The Lancet.

[43]  Neil Kaplowitz,et al.  Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis , 1981, Hepatology.

[44]  H. Towbin,et al.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[45]  R. Tiwari,et al.  Who is (are) the author(s) , 1977 .

[46]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[47]  J. P. Gray.  Addresses , 1869, Appetite.

[48]  I. Agapov,et al.  Humoral immune response to recombinant viral NS3 protein in patients with hepatitis C , 2005, Bulletin of Experimental Biology and Medicine.

[49]  D. Ouzan,et al.  Serological response to infection with different isolates of hepatitis C virus. , 2002, Journal of Viral Hepatitis.

[50]  K. Shimotohno,et al.  Identification of the domain required for trans-cleavage activity of hepatitis C viral serine proteinase. , 1994, Gene.